Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 8.9% – Time to Sell?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s stock price traded down 8.9% during mid-day trading on Wednesday . The stock traded as low as $29.98 and last traded at $30.00. Approximately 157,548 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 406,484 shares. The stock had previously closed at $32.92.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Morgan Stanley began coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price for the company. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Finally, Guggenheim started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.00.

Avalyn Pharma Trading Down 1.5%

The stock has a 50-day moving average price of $28.96. The company has a market cap of $1.32 billion and a price-to-earnings ratio of -1.36.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Activity at Avalyn Pharma

In other news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 34.06% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jill Carroll acquired 277,778 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.